Submitted:
30 May 2026
Posted:
02 June 2026
You are already at the latest version
Abstract
Objective: This multicenter retrospective real-world data study aimed to determine whether a preparation containing polyphenol, vitamin D3, vitamin C, and zinc added to antiviral therapy accelerates clinical recovery in children diagnosed with influenza by evaluating its effects on symptom duration and severity, time to fever resolution, and functional recovery.
Materials and Methods: This was a five-center, multicenter, retrospective, comparative real-world data analysis. A total of 128 patients aged 4-10 years with a clinical diagnosis of influenza were classified into a control group receiving antiviral therapy alone (n=64) and a combined polyphenol group receiving, in addition to antiviral therapy, a preparation containing polyphenol, vitamin D3, vitamin C, and zinc (n=64). Clinical data were obtained from electronic patient records and parent-reported information. Symptom severity (0-3 ordinal score), recovery time, and functional outcomes were assessed on Days 0, 3, 5, and 7. Continuous variables were compared using the independent-samples t test, categorical variables using the chi-square or Fisher exact test, and changes over time using a repeated-measures general linear model. Statistical significance was accepted as a two-sided p value of < 0.05.
Results: In this study including 128 pediatric patients, there were no significant differences between the combined polyphenol and control groups in demographic or baseline clinical characteristics (p>0.05). During follow-up, all symptom scores improved more rapidly and markedly in the combined polyphenol group than in the control group. By Day 3, significant differences were observed between groups in fever, cough, rhinorrhea, sore throat, fatigue, general condition, and physical activity scores (p< 0.001 for all parameters). By Day 5, almost complete resolution of symptoms (score 0) was observed in the combined polyphenol group, whereas symptoms persisted to a substantial extent in the control group (p< 0.001).
The time to fever resolution was significantly shorter in the combined polyphenol group (1.84±0.72 days vs 4.5±1.36 days; p< 0.001). Similarly, time to return to school (3.21±0.9 days vs 5.8±1.91 days; p< 0.001) and time for parents to return to work were significantly shorter in the combined polyphenol group (p< 0.001). The need for additional healthcare visits and antipyretic use was markedly lower in the combined polyphenol group (Day 3: 20.3% vs. 53.1%; Day 5: 0% vs. 15.6%; p< 0.001 for both comparisons).
Repeated-measures analyses showed a significant time-by-group interaction, indicating that the reduction in symptom scores occurred more rapidly and prominently in the combined polyphenol group (p< 0.001). Treatment was generally well tolerated in the combined polyphenol group; no serious adverse events were reported, and parent-reported tolerability was high (9.39±0.7).
Conclusion: This multicenter retrospective real-world data study shows that the preparation containing polyphenol, vitamin D3, vitamin C, and zinc added to antiviral therapy significantly reduces symptom duration and severity, accelerates clinical recovery, and markedly decreases healthcare utilization in children diagnosed with influenza. These findings suggest that this combination may represent an effective and well-tolerated adjuvant treatment option in the management of pediatric influenza.
Keywords:
influenza
; child
; polyphenol
; antiviral therapy
Introduction
Influenza is one of the most common acute respiratory tract infections in childhood and causes substantial morbidity and increased healthcare utilization every year. The disease, characterized by symptoms such as fever, cough, sore throat, and fatigue, is clinically important because of school absenteeism, parental work loss, and the risk of complications [1,2]. Antiviral treatments can reduce disease duration and the risk of complications, particularly when initiated within the first 48 hours after symptom onset; however, in some cases, symptoms may be prolonged and the inflammatory response may persist despite such treatment. This has increased interest in supportive and adjuvant treatment approaches [3,4].
Polyphenols are biologically active compounds with antioxidant, anti-inflammatory, and antiviral properties that can modulate the host response during viral infections. In addition, the regulatory effects of micronutrients such as vitamin C, vitamin D3, and zinc on the immune system provide potential mechanisms that may support clinical recovery in respiratory tract infections. When used in combination, these components may favorably influence the disease course through synergistic effects. Nevertheless, data on the effectiveness of such combinations under real-world conditions in pediatric influenza populations remain limited [5,6,7].
This study aimed to evaluate the effects of a polyphenol-based combination therapy on the clinical course of children diagnosed with influenza using multicenter real-world data.
Materials and Methods
This was a multicenter, retrospective, observational, comparative real-world data study conducted in the pediatric clinics of five tertiary hospitals in Türkiye. A total of 128 pediatric patients aged 4-10 years with a clinical and/or laboratory diagnosis of influenza were included.
The study was retrospective in design; all data were anonymized to protect patient confidentiality and the study was conducted in accordance with the principles of the Declaration of Helsinki. Approval was obtained from the relevant ethics committee (Istanbul Prof. Dr. Cemil Taşcıoğlu City Hospital Scientific Research Ethics Committee; Approval No: E-48670771-514.99-304610206; Approval Date: 11.02.2026).
Patients were divided into two groups: a control group receiving only standard antiviral therapy (oseltamivir phosphate) (n=64) and a combined polyphenol group receiving Ocean Polyphenols (Orzax Medicine Inc., Istanbul, Türkiye), in addition to antiviral therapy, containing polyphenol (standardized pomegranate peel–derived polyphenol, Biocell Pharmaceutical, Istanbul, Türkiye), vitamin D3, vitamin C, and zinc (n=64). The preparation used in the combined polyphenol group contained polyphenol (25 mg), vitamin D3 (400 IU), vitamin C (50 mg), and zinc (7.5 mg) per daily dose.
Clinical data were obtained from patient files, outpatient clinic records, and parent feedback. Assessments were performed on the day of diagnosis (Day 0) and on Days 3, 5, and, where available, 7. Symptom severity was assessed using 0-3 ordinal scores for fever, cough, rhinorrhea, sore throat, and fatigue. General condition and physical activity level scores, time to fever resolution, time to return to school, time for parents to return to work, additional healthcare visits, and the need for additional treatments were also recorded. Adverse events and treatment-related tolerability were evaluated separately.
Statistical analysis: Data were analyzed using SPSS version 26.0. Continuous variables are presented as mean±standard deviation and median (interquartile range), and categorical variables as n (%). The distribution of continuous variables was assessed using skewness and kurtosis coefficients. For between-group comparisons, independent-samples t tests were used for continuous variables and chi-square or Fisher exact tests for categorical variables. Changes over time and group effects were analyzed using a repeated-measures general linear model (Repeated Measures ANOVA) including time-by-group and time-by-treatment initiation timing interactions. All tests were two-sided, and statistical significance was accepted at p<0.05.
Results
A total of 128 pediatric patients were included in the study (combined polyphenol group: n=64; control group: n=64). No statistically significant differences were found between the groups in terms of age, sex, anthropometric measurements, influenza type, diagnostic method, or time to treatment initiation (p>0.05 for all variables). These findings indicate that the groups were homogeneous at baseline.
No significant association was found between the combined polyphenol and control groups in terms of sex distribution; the proportion of boys was 51.6% (n=33) in the combined polyphenol group, 54.7% (n=35) in the control group, and 53.1% (n=68) overall, while the proportion of girls was 48.4% (n=31), 45.3% (n=29), and 46.9% (n=60), respectively (p=0.723). In the subgroup distribution, the rate of early treatment was 29.7% (n=19) in the combined polyphenol group, 34.4% (n=22) in the control group, and 32.0% (n=41) overall; the rate of late treatment was 70.3% (n=45), 65.6% (n=42), and 68.0% (n=87), respectively (p=0.705). Regarding the diagnostic method, rapid testing was used in 17.2% (n=11) of the combined polyphenol group, 25.0% (n=16) of the control group, and 21.1% (n=27) overall, while PCR testing was used in 82.8% (n=53), 75.0% (n=48), and 78.9% (n=101), respectively (p=0.386). In terms of influenza type distribution, type A was detected in 45 patients in each group (70.3%), for a total of 90 patients (70.3%); type B was detected in 8 patients in each group (12.5%), for a total of 16 patients (12.5%); and type A+B was detected in 11 patients in each group (17.2%), for a total of 22 patients (17.2%) (Table 1).
There were also no significant differences between groups in antiviral dose (52.73±8.01 vs 53.2±7.99; p=0.741) or time to antiviral treatment initiation (3.44±1.51 vs 3.14±1.32 days; p=0.239). Skewness and kurtosis values for continuous variables were within the range of -3 to +3, indicating that the assumption of normal distribution was met for all parameters.
When changes in symptom severity scores over the follow-up period were examined, more rapid and marked improvement was observed in all symptoms in the combined polyphenol group compared with the control group. On Day 0, there were no significant differences between groups in symptom scores (p>0.05); however, by Day 3, significant differences favoring the combined polyphenol group were found in all scores for fever, cough, rhinorrhea, sore throat, fatigue, general condition, and physical activity level (p<0.001 for all parameters). In the Day 5 assessment, almost complete resolution of symptoms (score 0) was observed in the combined polyphenol group, whereas symptoms persisted substantially in the control group (p<0.001). On Day 7, all symptoms had completely resolved in the combined polyphenol group, while residual symptoms, particularly fatigue and reduced physical activity level, persisted in the control group (Table 2).
In the Day 3 assessment, symptom resolution rates were markedly higher in the combined polyphenol group: 76.6% vs 0% for fever, 70.3% vs 4.7% for cough, 71.9% vs 9.4% for rhinorrhea, and 78.1% vs 9.4% for sore throat (all p<0.001). The improvement rate for fatigue was 44.4% in the combined polyphenol group and 3.1% in the control group. By Day 5, nearly complete recovery was achieved for all major symptoms in the combined polyphenol group, whereas fatigue in particular persisted markedly in the control group (81.3% at a moderate-to-severe level).
When clinical recovery indicators were evaluated, the time to fever resolution was significantly shorter in the combined polyphenol group (1.84±0.72 days vs 4.5±1.36 days; p<0.001). Time to return to school was 3.21±0.9 days in the combined polyphenol group and 5.8±1.91 days in the control group (p<0.001). Similarly, the time for mothers and fathers to return to work was significantly shorter in the combined polyphenol group (2.49±1.22 days vs 6.14±1.97 days and 1.54±1.2 days vs 5.05±2.22 days, respectively; p<0.001 for both).
There were no significant differences between the combined polyphenol and control groups in antiviral dose or time to treatment initiation (52.73±8.01 vs 53.2±7.99; p=0.741 and 3.44±1.51 vs 3.14±1.32 days; p=0.239, respectively). In the combined polyphenol group, the start time was 3.44±1.51 days, and the mean duration of use was 5.89±1.48 days. In contrast, marked differences were observed between groups in clinical recovery parameters; the time to fever resolution (1.84±0.72 vs 4.5±1.36 days), time to return to school (3.21±0.9 vs 5.8±1.91 days), time for mothers to return to work (2.49±1.22 vs 6.14±1.97 days), and time for fathers to return to work (1.54±1.2 vs 5.05±2.22 days) were all significantly shorter in the combined polyphenol group (p<0.001 for all parameters). These results indicate that the combined polyphenol group experienced not only better symptom control but also a significant reduction in the functional burden of the disease and its socioeconomic impact on families (Table 3).
In the assessment of healthcare utilization and the need for additional treatment, the rate of additional healthcare visits on Day 3 was 20.3% in the combined polyphenol group and 53.1% in the control group (p<0.001). On Day 5, no additional healthcare visits were observed in the combined polyphenol group, whereas such visits continued in 15.6% of the control group (p=0.001). The need for additional antipyretic therapy was significantly lower in the combined polyphenol group, with a particularly marked difference on Days 3 and 5 (p<0.001). No significant differences were found between groups in antibiotic or antitussive use (p>0.05).
The need for antipyretics on Day 3 was 15.6% in the combined polyphenol group and 93.8% in the control group, representing a dramatic difference (p<0.001). By Day 5, the need for antipyretics had completely disappeared in the combined polyphenol group (0%), whereas it persisted in 48.4% of the control group. These findings indicate a marked reduction in the need for symptomatic medication in the combined polyphenol group.
The main effect of time was significant for all symptoms (p<0.001 for all parameters), and symptom scores decreased markedly throughout follow-up. The time-by-group interaction was significant for all symptoms (p<0.001), demonstrating that improvement in fever, cough, rhinorrhea, sore throat, fatigue, general condition, and physical activity level scores was faster and more pronounced in the combined polyphenol group. In the combined polyphenol group, symptom scores generally decreased dramatically by Day 3 and disappeared completely in most parameters by Day 5, whereas recovery in the control group was slower and some symptoms, particularly fatigue and restricted physical activity, persisted until Day 7. Although the time-by-early/late treatment interaction was not significant for most symptoms, significance was observed for fatigue (p=0.017), general condition (p=0.004), and physical activity (p=0.035), indicating that early treatment provided an additional advantage for some clinical parameters. The three-way interaction (time-by-group-by-early/late treatment) was significant only for the fever score (p=0.006) and was not significant for other symptoms. These findings strongly support a multidimensional and rapid clinical improvement in the course of influenza in the combined polyphenol group.
In the repeated-measures general linear model analysis, the main effect of time was significant for all symptom scores (p<0.001), and the time-by-group interaction was significant in favor of the combined polyphenol group (p<0.001). These findings demonstrate that symptom improvement occurred more rapidly and more markedly in the combined polyphenol group.
The effect of time on fever score was significant (p<0.001), and in the total sample, the fever score decreased from 2.91±0.29 on Day 0 to 1.28±1.14 on Day 3, 0.47±0.86 on Day 5, and 0.13±0.47 on Day 7. The time-by-group interaction was significant (p<0.001); in the combined polyphenol group, the fever score decreased markedly by Day 3 and disappeared completely from Day 5 onward, whereas it decreased more slowly in the control group and persisted until Day 7. Although the time-by-early/late treatment interaction was not significant (p=0.119), the three-way interaction (time-by-group-by-early/late treatment) was significant (p=0.006), and fever was observed to last longer particularly in late-treated patients in the control group. These findings indicate that fever resolution was faster and more pronounced in the combined polyphenol group.
In particular, the three-way interaction was significant for the fever score (p=0.006), showing that a rapid clinical response was achieved in the combined polyphenol group even among patients treated late. Similarly, the time-by-group interaction was significant across cough, rhinorrhea, general condition, and physical activity scores, supporting the multidimensional clinical effectiveness of the combined polyphenol group.
According to physician assessment, treatment tolerability was high, with 62.5% of cases rated as “very good.” Parent-reported tolerability was also high, with a mean score of 9.39±0.7 on a scale of 0 to 10.
All adverse events in both groups were mild and transient, and no event requiring treatment discontinuation was observed. In the combined polyphenol group, the median parent-reported tolerability score of 10 (9-10) indicates that the treatment has a high potential for adherence in clinical practice.
Discussion
This multicenter retrospective real-world data study demonstrates that the preparation containing polyphenol, vitamin D3, vitamin C, and zinc (Ocean Polyphenols) added to antiviral therapy provides a significant and marked improvement in the clinical course of children diagnosed with influenza. In our study, symptoms regressed more rapidly, fever resolved sooner, and functional recovery was markedly accelerated in the combined polyphenol group. In addition, the significant reductions in healthcare utilization and need for symptomatic treatment suggest that this combination may have favorable effects not only on symptom control but also on the burden placed on the healthcare system.
Although antiviral agents are effective in the treatment of influenza, particularly when initiated early, it is known that symptoms may be prolonged because the inflammatory response is not fully suppressed. Therefore, supportive approaches that can modulate the immune response in addition to antiviral therapy have come to the forefront in recent years. In addition to their antiviral effects, polyphenols can improve the clinical course of viral infections by regulating oxidative stress and cytokine responses. In vitro and clinical studies have shown that polyphenols can inhibit viral entry and replication and may shorten symptom duration in upper respiratory tract infections [8,9].
Among polyphenols, pomegranate peel extract is particularly noteworthy because of its high concentrations of punicalagins, ellagic acid derivatives, and flavonoids, which confer strong antiviral and anti-inflammatory properties. The total polyphenol content of pomegranate peel has been shown to be substantially higher than that of other parts of the fruit, and these compounds may inhibit viral entry and replication by binding to viral surface proteins. In addition, pomegranate peel-derived polyphenols have been reported to modulate the host inflammatory response by suppressing nuclear factor kappa-B (NF-κB) pathways and proinflammatory cytokine responses [10,11,12,13,14].
In respiratory viral infections such as influenza, both reducing viral load and balancing the excessive inflammatory response are critically important for accelerating clinical recovery. In this context, the rapid symptom regression and early clinical response observed in our study may be associated with the multifaceted effects of highly bioactive polyphenolic compounds, particularly pomegranate peel extract. These findings suggest that polyphenol sources may have not only supportive but also potentially disease-modifying effects.
Furthermore, the effects of micronutrients such as vitamin C, vitamin D3, and zinc on the immune system are well established. Vitamin C is known to enhance the interferon response, vitamin D to regulate antimicrobial peptide expression, and zinc to play a critical role in T-cell function and mucosal immunity [15,16,17,18,19,20,21,22]. When used in combination, these components may accelerate clinical recovery by exerting synergistic effects through different immunological pathways. The rapid symptom regression and marked shortening of recovery time observed in our study may be considered a clinical reflection of this synergistic effect.
One of the notable findings of our study was the marked decrease in symptom scores during the early period in the combined polyphenol group and the near-complete disappearance of symptoms by Day 5. The significant time-by-group interaction in repeated-measures analyses shows that the combined polyphenol group not only reduced symptom severity but also increased the speed of recovery. In addition, the marked reduction in parents’ time to return to work and in additional healthcare visits demonstrates that the treatment may also provide important benefits in terms of socioeconomic impact.
The strengths of this study include its multicenter design, reliance on real-world data, and simultaneous assessment of both clinical and functional outcomes. Nevertheless, some limitations should be acknowledged. The retrospective design may be limited by potential selection bias and missing records. In addition, the lack of a placebo-controlled randomized design limits the ability to establish a definitive causal relationship. However, the similarity of baseline characteristics between groups and the use of multivariable analyses support the reliability of the findings.
In conclusion, our study indicates that polyphenol-based combination therapy may be an effective adjuvant approach to antiviral therapy in children diagnosed with influenza. Further support from prospective randomized controlled studies will be important for the integration of these findings into clinical practice.
References
- Troeger, C.; Blacker, B.F.; Khalil, I.A.; Rao, P.C.; Cao, J.; Zimsen, S.R.M.; et al. Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections. Lancet 2019, 394, 1285–1300. [Google Scholar]
- Lafond, K.E.; Porter, R.M.; Whaley, M.J.; Suizan, Z.; Ran, Z.; Aleem, M.A.; et al. Global burden of influenza-associated lower respiratory tract infections. Lancet Respir. Med. 2021, 9, 130–142. [Google Scholar]
- Malosh, R.E.; Martin, E.T.; Heikkinen, T.; Brooks, W.A.; Whitley, R.J.; Monto, A.S. Efficacy and safety of oseltamivir in children. Clin. Infect. Dis. 2018, 66, 1492–1500. [Google Scholar] [CrossRef]
- Muthuri, S.G.; Venkatesan, S.; Myles, P.R.; Leonardi-Bee, J.; Al Khuwaitir, T.S.; Al Mamun, A.; et al. Effectiveness of neuraminidase inhibitors in reducing mortality. Lancet Respir. Med. 2016, 4, 395–404. [Google Scholar] [CrossRef]
- Calder, P.C. Nutrition, immunity and viral infections. Nutrients 2020, 12, 118. [Google Scholar] [CrossRef]
- Catanzaro, E.; Racchi, M.; Corsini, E.; Lanni, C. Immune-modulating effects of polyphenols. Int. J. Mol. Sci. 2020, 21, 7639. [Google Scholar] [CrossRef]
- Ganesan, K.; Xu, B. Polyphenols and immune function. Nutrients 2017, 9, 1107. [Google Scholar] [CrossRef]
- Colombo, E.; Sangiovanni, E.; Dell’Agli, M. Anti-viral properties of polyphenols. Molecules 2020, 25, 5412. [Google Scholar] [CrossRef]
- Ling, L.J.; Lu, Y.; Zhang, Y.Y.; Zhu, H.Y.; Tu, P.; Li, H.; et al. Flavonoids and antiviral activity. Viruses 2021, 13, 122. [Google Scholar] [CrossRef]
- Gullón, B.; Pintado, M.E.; Pérez-Álvarez, J.A.; Viuda-Martos, M. Pomegranate peel as a source of polyphenols. Food Chem. 2016, 196, 1094–1101. [Google Scholar] [CrossRef]
- Sood, A.; Gupta, R.; Kaur, J. Pomegranate peel extract antiviral mechanisms. J. Food Biochem. 2020, 44, e13164. [Google Scholar] [CrossRef]
- Ismail, T.; Sestili, P.; Akhtar, S. Pomegranate peel and fruit extracts: A review of potential anti-inflammatory and anti-infective effects. J. Ethnopharmacol. 2012, 143, 397–405. [Google Scholar] [CrossRef]
- Colombo, E.; Sangiovanni, E.; Dell’Agli, M. A review on the anti-viral properties of polyphenols: Possible application in influenza and other respiratory viral infections. Molecules 2020, 25, 5412. [Google Scholar] [CrossRef]
- Afaq, F.; Saleem, M.; Krueger, C.G.; Reed, J.D.; Mukhtar, H. Anthocyanin- and hydrolyzable tannin-rich pomegranate fruit extract modulates MAPK and NF-κB pathways and inhibits skin tumorigenesis in vivo. Int. J. Cancer 2005, 113, 423–433. [Google Scholar] [CrossRef]
- Arıca, Seçil; Arıca, Vefik; Dağ, Hüseyin; Kaya, Ayşen; Hatipoğlu, Sami; Fenercioğlu, Ayşen; Karatekin, Güner. Serum Zinc levels in children of 0-24 months diagnosed with pneumonia admitted to our clinic. Int. J. Clin. Exp. Med. 2011, 4(3), 227–233. [Google Scholar] [CrossRef] [PubMed]
- Şilfeler, İbrahim; Cansaran Tanidir, İbrahim; Arıca, Vefik. Risk factors for lower respiratory tract infections in children. Pak. J. Med. Sci. 2012, 28(3), 488–491. [Google Scholar] [CrossRef]
- Arıca, Vefik; Şilfeler, İbrahim; Onur, Hatice; Dağ, Hüseyin; Gülbayzar, Sayat; Obut, Ömer. The incidence of RSV infection in the cases hospitalized with bronchiolitis diagnosis and the relevant clinical particulars. Pediat Ther. 2012, 2, 4. [Google Scholar] [CrossRef]
- Hemilä, H.; Chalker, E. Vitamin C for respiratory infections. Nutrients 2017, 9, 339. [Google Scholar] [CrossRef] [PubMed]
- Martineau, A.R.; Jolliffe, D.A.; Hooper, R.L.; Greenberg, L.; Aloia, J.F.; Bergman, P.; et al. Vitamin D supplementation to prevent acute respiratory infections. BMJ 2017, 356, i6583. [Google Scholar] [CrossRef]
- Read, S.A.; Obeid, S.; Ahlenstiel, C.; Ahlenstiel, G. Zinc and antiviral immunity. Nutrients 2019, 11, 1010. [Google Scholar] [CrossRef]
- Dag, H.; Kaya, A.; Arica, V.; Hatipoglu, S.; Karatekin, G. Plasma and Urine Malondialdehyde Levels of Infants with Acute Bronchopneumonia in the Assessment of Oxidative Response. J. Infect. Dis. Med. 2018, 3, 1. [Google Scholar] [CrossRef]
- Arıca, Vefik; Adıgüzel, Taner. The Effect of Intranasal Olopatadine Hydrochloride on Influenza A and B Symptoms In Children: A Clinical Observation and Comparative Evaluation. Chron. Precis Med. Res. 2025, 6(2), 48.–51. [Google Scholar]
Table 1.
Comparison of demographic and baseline clinical characteristics between the combined polyphenol and control groups.
Table 1.
Comparison of demographic and baseline clinical characteristics between the combined polyphenol and control groups.
| Group | p | ||||
|---|---|---|---|---|---|
| Combined Polyphenol | Control | Total | |||
| n (%) | n (%) | n (%) | |||
| Sex | Male | 33(%51,6) | 35(%54,7) | 68(%53,1) | 0,723 |
| Female | 31(%48,4) | 29(%45,3) | 60(%46,9) | ||
| Subgroup [Early treatment (≤48 h); Late treatment (>48 h)] | Early treatment | 19(%29,7) | 22(%34,4) | 41(%32) | 0,705 |
| Late treatment | 45(%70,3) | 42(%65,6) | 87(%68) | ||
| Diagnostic Method | Rapid test | 11(%17,2) | 16(%25) | 27(%21,1) | 0,386 |
| PCR | 53(%82,8) | 48(%75) | 101(%78,9) | ||
| Influenza Type | A | 45(%70,3) | 45(%70,3) | 90(%70,3) | 1,000 |
| B | 8(%12,5) | 8(%12,5) | 16(%12,5) | ||
| A+B | 11(%17,2) | 11(%17,2) | 22(%17,2) | ||
Chi-square test.
Table 2.
Distribution of symptom severity scores on follow-up days according to the combined polyphenol and control groups.
Table 2.
Distribution of symptom severity scores on follow-up days according to the combined polyphenol and control groups.
| Day (0) | Day (3) | Day (5) | Day (7) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | p | Group | p | Group | p | Group | p | ||||||
| Combined Polyphenol | Control | Combined Polyphenol | Control | Combined Polyphenol | Control | Combined Polyphenol | Control | ||||||
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | ||||||
| Fever Score | 0 | 0(%0) | 0(%0) | 0,364 | 49(%76,6) | 0(%0) | 0,000 | 63(%100) | 31(%48,4) | 0,000 | 63(%100) | 55(%85,9) | 0,003 |
| 1 | 0(%0) | 0(%0) | 11(%17,2) | 4(%6,3) | 0(%0) | 10(%15,6) | 0(%0) | 2(%3,1) | |||||
| 2 | 4(%6,3) | 8(%12,5) | 4(%6,3) | 40(%62,5) | 0(%0) | 19(%29,7) | 0(%0) | 7(%10,9) | |||||
| 3 | 60(%93,8) | 56(%87,5) | 0(%0) | 20(%31,3) | 0(%0) | 4(%6,3) | 0(%0) | 0(%0) | |||||
| Cough Score | 0 | 1(%1,6) | 0(%0) | 0,424 | 45(%70,3) | 3(%4,7) | 0,000 | 63(%100) | 38(%59,4) | 0,000 | 63(%100) | 55(%85,9) | 0,003 |
| 1 | 0(%0) | 0(%0) | 16(%25) | 4(%6,3) | 0(%0) | 7(%10,9) | 0(%0) | 4(%6,3) | |||||
| 2 | 6(%9,4) | 10(%15,6) | 3(%4,7) | 40(%62,5) | 0(%0) | 16(%25) | 0(%0) | 5(%7,8) | |||||
| 3 | 57(%89,1) | 54(%84,4) | 0(%0) | 17(%26,6) | 0(%0) | 3(%4,7) | 0(%0) | 0(%0) | |||||
| Rhinorrhea Score | 0 | 2(%3,1) | 0(%0) | 0,499 | 46(%71,9) | 6(%9,4) | 0,000 | 63(%100) | 43(%67,2) | 0,000 | 63(%100) | 56(%87,5) | 0,006 |
| 1 | 0(%0) | 0(%0) | 16(%25) | 5(%7,8) | 0(%0) | 7(%10,9) | 0(%0) | 6(%9,4) | |||||
| 2 | 8(%12,5) | 10(%15,6) | 2(%3,1) | 40(%62,5) | 0(%0) | 13(%20,3) | 0(%0) | 2(%3,1) | |||||
| 3 | 54(%84,4) | 54(%84,4) | 0(%0) | 13(%20,3) | 0(%0) | 1(%1,6) | 0(%0) | 0(%0) | |||||
| Sore Throat Score | 0 | 0(%0) | 0(%0) | 1,000 | 50(%78,1) | 6(%9,4) | 0,000 | 63(%100) | 45(%70,3) | 0,000 | 63(%100) | 60(%93,8) | 0,119 |
| 1 | 0(%0) | 0(%0) | 12(%18,8) | 4(%6,3) | 0(%0) | 6(%9,4) | 0(%0) | 2(%3,1) | |||||
| 2 | 9(%14,1) | 10(%15,6) | 2(%3,1) | 47(%73,4) | 0(%0) | 12(%18,8) | 0(%0) | 2(%3,1) | |||||
| 3 | 55(%85,9) | 54(%84,4) | 0(%0) | 7(%10,9) | 0(%0) | 1(%1,6) | 0(%0) | 0(%0) | |||||
| Fatigue Score | 0 | 0(%0) | 0(%0) | 1,000 | 28(%44,4) | 2(%3,1) | 0,000 | 62(%98,4) | 3(%4,7) | 0,000 | 63(%100) | 18(%28,1) | 0,000 |
| 1 | 0(%0) | 0(%0) | 28(%44,4) | 4(%6,3) | 1(%1,6) | 6(%9,4) | 0(%0) | 5(%7,8) | |||||
| 2 | 12(%18,8) | 13(%20,3) | 7(%11,1) | 53(%82,8) | 0(%0) | 52(%81,3) | 0(%0) | 41(%64,1) | |||||
| 3 | 52(%81,3) | 51(%79,7) | 0(%0) | 5(%7,8) | 0(%0) | 3(%4,7) | 0(%0) | 0(%0) | |||||
| General Condition Score | 0 | 0(%0) | 0(%0) | 1,000 | 53(%82,8) | 8(%12,5) | 0,000 | 63(%100) | 39(%60,9) | 0,000 | 63(%100) | 54(%84,4) | 0,002 |
| 1 | 0(%0) | 0(%0) | 11(%17,2) | 7(%10,9) | 0(%0) | 12(%18,8) | 0(%0) | 9(%14,1) | |||||
| 2 | 18(%28,1) | 18(%28,1) | 0(%0) | 48(%75) | 0(%0) | 13(%20,3) | 0(%0) | 1(%1,6) | |||||
| 3 | 46(%71,9) | 46(%71,9) | 0(%0) | 1(%1,6) | 0(%0) | 0(%0) | 0(%0) | 0(%0) | |||||
| Physical Activity Level Score | 0 | 0(%0) | 0(%0) | 0,692 | 51(%79,7) | 9(%14,1) | 0,000 | 63(%100) | 41(%64,1) | 0,000 | 63(%100) | 52(%81,3) | 0,000 |
| 1 | 1(%1,6) | 0(%0) | 13(%20,3) | 9(%14,1) | 0(%0) | 15(%23,4) | 0(%0) | 11(%17,2) | |||||
| 2 | 16(%25) | 19(%29,7) | 0(%0) | 46(%71,9) | 0(%0) | 8(%12,5) | 0(%0) | 1(%1,6) | |||||
| 3 | 47(%73,4) | 45(%70,3) | 0(%0) | 0(%0) | 0(%0) | 0(%0) | 0(%0) | 0(%0) | |||||
Chi-square test.
Table 3.
Comparison of treatment characteristics and recovery process indicators between the combined polyphenol and control groups.
Table 3.
Comparison of treatment characteristics and recovery process indicators between the combined polyphenol and control groups.
| Group | P | ||||||
|---|---|---|---|---|---|---|---|
| Combined Polyphenol | Control | Total | |||||
| Mean±sd | Median (Q25-Q75) | Mean±sd | Median (Q25-Q75) | Mean±sd | Median (Q25-Q75) | ||
| Antiviral Dose | 52,73±8,01 | 52,5(45_75) | 53,2±7,99 | 60(45_75) | 52,97±7,97 | 60(45_75) | 0,741 |
| Antiviral Start Time (day) | 3,44±1,51 | 3(1_7) | 3,14±1,32 | 3(1_5) | 3,29±1,42 | 3(1_7) | 0,239 |
| Combined Polyphenol Start Time (day) | 3,44±1,51 | 3(1_7) | |||||
| Duration of Combined Polyphenol Use | 5,89±1,48 | 5(5_10) | |||||
| Time to Fever Resolution (day) | 1,84±0,72 | 2(1_3) | 4,5±1,36 | 5(3_7) | 3,18±1,72 | 3(1_7) | 0,000 |
| Time to Return to School (day) | 3,21±0,9 | 3(2_5) | 5,8±1,91 | 5(3_10) | 4,51±1,98 | 5(2_10) | 0,000 |
| Time for Mother to Return to Work (day) | 2,49±1,22 | 3(0_5) | 6,14±1,97 | 5(3_10) | 4,33±2,46 | 5(0_10) | 0,000 |
| Time for Father to Return to Work (day) | 1,54±1,2 | 1(0_5) | 5,05±2,22 | 5(0_10) | 3,31±2,51 | 3(0_10) | 0,000 |
T test.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
